Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Employees - 1094, CEO - Thomas William Burns, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 31.48, Piotroski Score(max is 10): 4, Working Capital: $452924000, Total Assets: $979529000, Retained Earnings: $-969272000, EBIT: -169203000, Total Liabilities: $262255000, Revenue: $690332000

AryaFin Target Price - $-45.28 - Current Price $ - Analyst Target Price $